JFB et GP2A 2013

Orateurs confirm

Orateurs Confirmés

L11 - Computer assisted drug design of protein therapeutics

Dr Nicolas BAURIN
(SANOFI-AVENTIS, Vitry sur Seine, France)

L05 - Développement d'un nucléotide antisens actif par voie orale pour le traitement des MICI

Dr Salvatore BELLINVIA
(GIULIANI SPA, Milano, Italy)

L01 - From PPARg agonists to Selective PPARg Modulator (SPPARM): a long story!

Dr Catherine DACQUET
(INSTITUT DE RECHERCHES SERVIER, Suresnes, France)

L04 - Nouvelles perspectives thérapeutiques dans les maladies inflammatoires intestinales

Prof. Pierre DESREUMAUX
(UNIVERSITÉ LILLE 2, Lille, France)

L06 - Design and synthesis of aminosteroids and steroidal neuromuscular blocking agents

Prof. Xianming HU
(WUHAN UNIVERSITY, Wuhan, Hubei, China)

L07 - L'oligomérisation des récepteurs couplés aux protéines G et complexes protéiques associés: de nouvelles opportunités pour le drug design

Dr Ralf JOCKERS
(UNIVERSITÉ PARIS DESCARTES, Paris, France)

L09 - The dynamics of protein-DNA recognition in the telomere

Dr Charles LAUGHTON
(UNIVERSITY PARK NOTTINGHAM, Nottingham, United Kingdom)

L08 - Structure, function and inhibition of human protein kinase CK2

Prof. Marc LE BORGNE
(UNIVERSITÉ CLAUDE BERNARD LYON 1, Lyon, France)

L02 - Serendipity: facteur de diversité

JFB et GP2A 2013

Orateurs confirm

Prof. Benoit RIGO
(HEI, Lille, France)

L03 - Myéloperoxydase: cible thérapeutique dans les syndromes inflammatoires chroniques

Mr Pierre VAN ANTWERPEN
(ULB, Bruxelles, Belgium)

L10 - Dual regulation of estrogen receptor with novel selective estrogen receptor modulators (SERMs)

Prof. Haibing ZHOU
(WUHAN UNIVERSITY, Wuhan, China)

Communications orales

OC03 - PEA reduces colon and systemic inflammation in mice models of crohn's disease

Ms Mireille AL HOUAYEK
(UCL, Bruxelles, Belgium)

OC05 - Novel development in coumarins as FXIIa inhibitors: Improvement of solubility

Mrs Charlotte BOUCKAERT
(UNAMUR, Namur, Belgium)

OC04 - Nouvelle voie de synthèse de derivés furo[3,2-b]pyridiniques à activité mélatoninergique

Ms Audrey COUHERT
(ICOA, Orléans, France)

OC10 - Design and synthesis of 2-indolyl-thieno[2.3-d]pyrimidinones as potential inhibitors of VEGFR2

Dr Stéphanie HESSE
(UNIVERSITÉ DE LORRAINE, Metz, France)

OC14 - An unusual borontribromide-mediated, one-pot bromination/cyclisation reaction. application to the synthesis of a highly strained cyclopenta[1,3]cycopropa[1,2-b]pyrrolizin-8-one

Mr Jean-Pierre JOURDAN
(CERMN, Caen, France)

OC02 - Dynamique du complexe CD1d-ligand: Hypothèse mécanistique sur le profil d'activation des iNKT

Mr Xavier LAURENT
(INSTITUT DE CHIMIE PHARMACEUTIQUE ALBERT LESPAGNOL , Lille, France)

OC01 - Acyl-benzothiazol-2-one: a privileged scaffold in the design of PPAR modulators

Dr Nicolas LEBEGUE
(UNIVERSITÉ LILLE 2, Lille, France)

OC08 - Discovery of highly potent, selective and safe reversers of BCRP-mediated multidrug resistance

Ms Florine LECERF-SCHMIDT
(UJF, Grenoble, France)

OC06 - Synthesis and evaluation of harmine derivatives as new cytostatic compounds on cancerous cells

JFB et GP2A 2013

Orateurs confirm

Mrs Celine MEINGUET
(UNAMUR, Namur, Belgium)

OC11 - 1,4-dihydropyridines as antiproliferative and multidrug resistance reversal agents

Mr Conor O'SHEA
(TRINITY COLLEGE DUBLIN, Dublin, Ireland)

OC13 - Asymmetric synthesis of Rhodotorulic acid analogues with potential antibacterial activities

Ms Marine PILLON
(UNIVERSITÉ DE PICARDIE JULES VERNE, Amiens, France)

OC07 - Antiplasmodial SARs in 2-trichloromethylazaheterocyclic series

Dr Nicolas PRIMAS
(FACULTÉ DE PHARMACIE DE MARSEILLE, Marseille, France)

OC09 - Metalloprotease inhibitors targeting: new strategy for chondrosarcoma treatment

Dr Magali VIVIER
(UMR 990 INSERM, Clermont-Ferrand, France)